




Taibah University
Journal of Taibah University Medical Sciences

www.sciencedirect.com



Letter to the Editor

First documented human case of mpox: Implications for global surveillance, public health and policy

Olalekan John Okesanya, MPH^{a,b}, Mohamed Mustaf Ahmed, MD^{c,d},
Uthman Okikiola Adebayo, BMLS^{a,e,*}, Tolutope Adebimpe Oso, PhD^{a,f} and
Don Eliseo Lucero-Priso III, PhD^{g,h,i}

^a Department of Medical Laboratory Science, Neuropsychiatric Hospital, Aro, Abeokuta, Nigeria

^b Faculty of Medicine, Department of Public Health and Maritime Transport, University of Thessaly, Volos, Greece

^c Faculty of Medicine and Health Sciences, SIMAD University, Mogadishu, Somalia

^d SIMAD Institute for Global Health, SIMAD University, Mogadishu, Somalia

^e Department of Medical Laboratory Science, College of Basic Health Sciences, Achievers University, Owo, Ondo State, Nigeria

^f Department of Medical Laboratory Science, McPherson University, Seriki Sotayo, Ogun State, Nigeria

^g Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom

^h Research and Innovation Office, Southern Leyte State University, Sogod, Southern Leyte, Philippines

ⁱ Center for Research and Development, Cebu Normal University, Cebu, Philippines

Received 13 June 2025; revised 16 June 2025; accepted 19 June 2025;

Keywords Clade Ib; Emerging infectious diseases; Genomic surveillance; Mpox virus; Public health policy; Zoonotic diseases

© 2025 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Dear Editor,

The first documented human infection with the mpox virus clade Ib in China represents a pivotal event for global zoonotic disease surveillance, emphasizing the need to reinforce public health strategies that monitor and curb the spread of high-risk viral pathogens.¹ Mpox, formerly known as monkeypox, has long been endemic to the African continent; however, the appearance of clade Ib in China signals an alarming geographic expansion of a variant

linked to greater clinical severity and transmissibility. This emergence calls for immediate international collaboration to enhance epidemiological monitoring, diagnostic capacity, and cross-border policy preparedness.^{1,2} The index case involved a 28-year-old South African woman residing in Zhejiang Province who had sexual contact with an asymptomatic male traveler from the Democratic Republic of Congo. Genomic sequencing performed on January 2, 2025, identified the strain as MPXV ZJ-JX-2025, a clade Ib virus showing high homology with sequences from the DRC. Although the patient recovered with supportive care, viral shedding from skin lesions, urine, and scabs persisted for up to 20 days, underscoring the challenges of containment.³ Unlike typical clade IIB cases, which often present with genital lesions and predominantly affect men who have sex with men, this case lacked oral and genital lesions, indicating a broader transmission profile and highlighting the threat of silent transmission chains.^{1,3} Virological investigations revealed high viral loads in skin lesions and scabs, while urine specimens remained persistently positive, contradicting assumptions that urine poses minimal risk. These findings support multisite sampling to improve diagnostic sensitivity and refine infection control measures in both healthcare and community settings.³ The detection of MPXV DNA in environmental samples linked to an asymptomatic carrier further exposes gaps in surveillance systems that focus only on symptomatic individuals and demonstrates the need for environmental and serological

* Corresponding address: Department of Medical Laboratory Science, Neuropsychiatric Hospital, Abeokuta, Nigeria.

E-mail: uthmanadebayo85@gmail.com (U.O. Adebayo)

Peer review under responsibility of Taibah University.



Production and hosting by Elsevier

screening.^{1,4} Chinese authorities responded promptly by isolating the patient, performing comprehensive contact tracing, and decontaminating affected environments, thereby modeling the best practices for outbreak containment.³ Nevertheless, the presence of clade Ib in at least 12 countries outside Africa, including the United States, the United Kingdom, Sweden, and India, confirms its pandemic potential. The World Health Organization's designation of mpox as a Public Health Emergency of International Concern in August 2024 was appropriate; however, the global community must act more proactively.⁵

Renewed emphasis on genomic surveillance, especially at international ports of entry, is essential for the rapid identification of emerging variants. Public health agencies should update diagnostic protocols to reflect the evolving clinical and virological characteristics of clade Ib, and clinicians must maintain a high index of suspicion, even in atypical presentations. Vaccination strategies warrant reassessment to extend protection to groups at elevated risk owing to occupational exposure or sexual behavior.⁶ Stronger international data-sharing platforms are also critical; timely access to epidemiological and genomic data through mechanisms such as the WHO, GISAID, and regional surveillance networks will underpin effective responses. In parallel, sustained investment in public health infrastructure and community engagement in low- and middle-income countries, where mpox is endemic, will help diminish the viral reservoir from which new variants arise.^{7,8} The identification of the MPXV clade Ib in China is a sentinel event that illustrates how rapidly zoonotic threats can transcend borders. It should galvanize national and global health agencies to reinforce surveillance, broaden the diagnostic criteria, strengthen infection control, and prepare for the next phase of the mpox pandemic. Clade Ib's emergence is not a local anomaly; it is a global public-health challenge that demands coordinated, science-driven action.⁹

References

1. Sun J, Zhou L, Wu B, Chen Z, He Y, Wang X, et al. Characteristics of the first confirmed case of human infection with mpox virus clade Ib in China. *Nat Commun* 2025; 16: 4888. <https://doi.org/10.1038/s41467-025-60217-2>.
2. Adigun OA, Okesanya OJ, Ahmed MM, Ukoaka BM, Lucero-Prisno DE, Onyeaghala EO, et al. Syndemic challenges: addressing the resurgence of mpox amidst concurrent outbreaks in the DRC. *Transbound Emerg Dis* 2024; 2024. <https://doi.org/10.1155/tbed/1962224>.
3. Pan W, Ge R, Zhu G, Tian Y, Yan Y, Fu X, et al. The first reported case of monkeypox virus clade Ib infection in China—clinical presentation and epidemiologic implications. *Int J Infect Dis* 2025; 155:107881. <https://doi.org/10.1016/j.ijid.2025.107881>.
4. Pan D, Nazareth J, Sze S, Martin CA, Decker J, Fletcher E, et al. Transmission of monkeypox/mpox virus: a narrative review of environmental, viral, host, and population factors in relation to the 2022 international outbreak. *J Med Virol* 2023; 95. <https://doi.org/10.1002/jmv.28534>.
5. Jin S, Gan G, Endo A, Prem K, Tan RKJ, Lim JT, et al. Modelling the potential spread of clade Ib MPXV in Asian cities. *BMJ Public Health* 2025; 3:e002285. <https://doi.org/10.1136/bmjph-2024-002285>.
6. Ochola R. The case for genomic surveillance in Africa. *Trop Med Infect Dis* 2025; 10: 129. <https://doi.org/10.3390/tropicalmed10050129>.
7. Adebisi BO. Mpox alert: COVID-19's hard-earned lessons put to the test. *One Health* 2025; 20:101003. <https://doi.org/10.1016/j.onehlt.2025.101003>.
8. Ahmed MM, Dirie NI, Okesanya OJ, Lucero-Prisno DE. Mpox in East Africa: confronting a public health emergency. *J Taibah Univ Med Sci* 2024; 19: 992–994. <https://doi.org/10.1016/j.jtumed.2024.09.010>.
9. Srivastava S, Laxmi Sharma K, Sridhar SB, Talath S, Shareef J, et al. Clade Ib: a new emerging threat in the Mpox outbreak. *Front Pharmacol* 2024; 15. <https://doi.org/10.3389/fphar.2024.1504154>.

How to cite this article: Okesanya OJ, Ahmed MM, Adebayo UO, Oso TA, Lucero-Prisno DE. First documented human case of mpox: Implications for global surveillance, public health and policy. *J Taibah Univ Med Sc* 2025;20(4):437–438.